NASDAQ NMS - GLOBAL MARKET · CDXS
-2.27% · -$0.0300 · Vol Not reported
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Codexis Inc

Codexis Inc

Life Sciences Tools & Services
$1.29
Card
Relationship Map

Follow $CDXS

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $CDXS by email

Veridion Score

BETALOW CONF · 6 of 6 factors measuredMethodology
CDXS
Codexis Inc
Wed Oct 14 · market closed · Markets closed · resumes Thu 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

57/ 100
Veridion Score
Middle range · LOW confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →or $250/yr
Cancel anytime · or Reserve · $79/moor $790/yr
Confidence: LOW · 6 of 6 factors measured · Wed Oct 14 · market closed · Markets closed · resumes Thu 9:30 ET
Share on X →
AI Analysis
Sovereign

Why is CDXS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Codexis Inc
INDUSTRIAL ORGANIC CHEMICALS
Listed since
2010
Employees
146
Country
US

Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$1.30
Day high
$1.34
Day low
$1.27
Previous close
$1.32
52W high
$2.85
-54.74% from high
52W low
$0.9800
17% of range
Market cap
$144.5M
EPS
$-0.3388
Beta
0.90
Shares out
109.5M
Avg volume
831.4K
VWAP
$1.32
Last session
Price history computed in-house
1W
-5.15%
1M
-7.86%
3M
-42.41%
1Y
-52.92%
YTD
-20.86%
SMA 50 $1.47 · below
SMA 200 $1.84 · below
52W position 17%

CDXS overview

Veridion Score
57
Registered · 2026-10-14
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CDXS.Congress disclosuresOpen receipt and filing context for CDXS.MethodologyReview score inputs, coverage rules, and limitations.
Public disclosures

Congress activity in CDXS

Congress trackerOpen ticker disclosure ledger →

1 filers · 1 buys · 0 sells (0 labeled S (partial)) · Apr 6, 2018 to Apr 6, 2018 · House 1 / Senate 0

All available history · Latest 0 of 1 lines · Read Oct 15, 2026, 12:25 AM UTC

No trade rows are included in this public preview.

See all 1 trade, filters and CSV — Sovereign $25/mo
Federal contracts

CDXS contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CDXS in this window.
Lobbying spend

CDXS lobbying filings, year to date.

Registered lobbying filings matched to Codexis Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CDXS in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for CDXS.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.